Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine
Semaglutide affects digestion, food intake, and how the body uses energy
The ongoing 72-week STEP UP T2D trial will investigate semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss
When the molecule is made, tested, and dosed under protocol, the dominant risks are GI tolerability and the known incretin-class effects physicians are learning to manage
Specific safety concerns related to semaglutide included an increase in gallbladder disorders, but there was no evidence of drug-induced liver injury
US$ 21.87
US$ 26.16
US$ 21.96
US$ 25.46
US$ 20.68
US$ 27.17
